Evidence map›Paper›PMID 31247632›Full record

ArticleEuropean journal of gastroenterology & hepatology2019

Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival.

Aline L Chagas, Guilherme E G Felga, Marcio A Diniz, Renato F Silva, Angelo A Mattos, Rita C M A Silva, Ilka F S F Boin, José H P Garcia, Agnaldo S Lima, Julio C U Coelho and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of gastroenterology & hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Aline L ChagasDepartment of Gastroenterology.
Guilherme E G FelgaLiver Transplantation Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Marcio A DinizDepartment of Gastroenterology.
Renato F SilvaServiço de Gastroenterologia e Unidade de Transplante de Fígado, Hospital de Base - FUNFARME, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto.
Angelo A MattosDepartment of Gastroenterology, Fundação Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre.
Rita C M A SilvaServiço de Gastroenterologia e Unidade de Transplante de Fígado, Hospital de Base - FUNFARME, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto.
Ilka F S F BoinUnit of Liver Transplantation, State University of Campinas, Campinas.
José H P GarciaCeará Unit of Liver Transplantation, Department of Surgery and Liver Transplantation, Federal University of Ceará, Fortaleza.
Agnaldo S LimaSchool of Medicine, Federal University of Minas Gerais, Belo Horizonte.
Julio C U CoelhoSurgery Department, Federal University of Parana, Curitiba.
Paulo L BittencourtUnit of Gastroenterology and Hepatology, Portuguese Hospital of Salvador, Bahia.
Venâncio A F AlvesDepartment of Pathology, University of São Paulo School of Medicine.
Luiz A C D'AlbuquerqueDepartment of Gastroenterology.
Flair J CarrilhoDepartment of Gastroenterology.
Brazilian HCC Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiver transplantation (LT) is the treatment of choice for patients with unresectable early hepatocellular carcinoma (HCC). Post-LT HCC recurrence rates range from 8 to 20% and still impact on overall survival (OS). The aim of our study was to evaluate the impact of HCC recurrence on post-LT survival and analyze prognostic factors among those patients with recurrence. PATIENTS AND

methodsWe carried out a national, multicenter, retrospective cohort study in Brazil. Medical records of 1119 LT recipients with HCC were collected. Data from patients with post-LT HCC recurrence were analyzed and correlated with post-relapse survival.

resultsOS of the 1119 patients included in the study was 63% over 5 years. Post-LT HCC recurrence occurred in 86 (8%) patients. The mean time to recurrence was 12 months. Sites of recurrence were extrahepatic in 55%, hepatic in 27%, and both hepatic and extrahepatic in 18%. Recurrence treatment was performed in 50 (64%) cases, mostly with sorafenib. Post-relapse survival rates were 34% at 1 year and 13% at 5 years. Univariable analysis identified α-fetoprotein more than 1000 ng/ml at relapse, recurrence treatment, extrahepatic location, and time to recurrence more than 2 years as prognostic factors. In multivariable analysis, recurrence treatment, extrahepatic location, and time to recurrence more than 2 years were independent predictors of better survival.

conclusionIn a large Brazilian cohort of LT recipients with HCC, post-LT HCC recurrence occurred in 8% and impacted significantly on the OS. Patients with early recurrence presented a worse prognosis. However, treatment of recurrence improved outcomes, highlighting the importance of early diagnosis.

Indexed as

Liver TransplantationAgedBrazilCarcinoma, HepatocellularDisease-Free SurvivalFemaleHumansLiver NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesSurvival Rate

Identifiers

PMID31247632
PMCPMC6687037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.